Baxter sells its Vero cell technology; Santen, Durect form drug delivery partnership;

> Baxter International ($BAX) entered into a definitive agreement to sell its Vero cell-based technology for vaccine production to Nanotherapeutics. Release

> Santen Pharmaceutical now has exclusive worldwide rights to sell a sustained-release product that uses Durect's saber technology. The terms of an agreement between the two companies calls for Santen to pay Durect a fee of $2 million. Story

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.